WILSON, N.C., July 30, 2021 /PRNewswire/ — The biggest industrial hemp analysis, extraction and manufacturing firm within the jap U.S. has adopted a brand new title, Averix Bio, to sign its emergence as the one 21 CFR Half 210 and Half 211 cannabinoid provider within the U.S. Positioned in North Carolina’s Analysis Triangle area, the corporate previously often called Avient Biosciences has a 200,000-square-foot facility on a 36-acre campus that features pharmaceutical- and food-grade analysis and manufacturing suites, on-site analytical testing laboratories, and climate-controlled biomass storage amenities.
Avient Biosciences modified its title to Averix Bio to sign transfer to 21 CFR Half 210 & Half 211-compliant CBD provider
With the 21 CFR Half 210 and Half 211 compliance, the corporate will each associate with life sciences corporations which might be exploring the usage of cannabinoids as an lively pharmaceutical ingredient (API) and pursue its personal completed pharmaceutical merchandise to deal with opioid habit, epilepsy and trauma-induced psychological well being problems.
“Our aim during the last 18 months has been to introduce the next degree of compliance and manufacturing rigor to cannabinoid manufacturing,” mentioned Miles Wright, the corporate’s CEO. “At this time’s title change to Averix Bio displays us nearing our begin as a producer of merchandise which might be 21 CFR Half 210 and Half 211–compliant, a milestone that may assist drive analysis, launch API and completed merchandise, and collaborate with companions as a science-driven, risk-based producer.”
Mr. Wright famous that the corporate’s high quality assurance staff has greater than six many years of cGMP pharmaceutical expertise, having labored on a number of merchandise at GlaxoSmithKline, Pfizer, Novartis, Roche and Genentech, from medical Part 1 via business manufacturing.
That have offers peace-of-mind for premier pharmaceutical producers that want batch samples, “seed-to-shelf” tracing and excessive ranges of compliance.
“Basically, we wish to be the ingredient associate of alternative for individuals doing medical-grade analysis on cannabinoids anyplace on the earth,” mentioned Mark Ward, vice chairman of gross sales and advertising and marketing. “We’re keen on medical breakthroughs utilizing cannabinoids. There are a variety of sharp minds exploring how these elements might be a part of potential remedies for a broad vary of well being points, from pimples to Crohn’s Illness to most cancers, however there’s nonetheless far more analysis to be carried out.”
At this time’s announcement comes on the heels of a number of key process-, market- and regulatory-related milestones for Averix Bio. The corporate has expanded its footprint to supply pharma- and food-grade cannabinoid merchandise to purchasers within the EU and South America and plans to maintain its North Carolina headquarters as its operational hub because it companions with potential pharmaceutical producers in new markets.
“We have been strategic in our choice to find close to Analysis Triangle Park due to its international status for main pharmaceutical analysis, our potential to supply high-quality hemp straight from North Carolina farmers, and the entry we might should a technical, extremely expert workforce,” Mr. Wright mentioned. “Those self same three dynamics are poised to make North Carolina, in our view, a worldwide pressure in cannabinoid analysis within the years forward.”
Based in 2018, Averix Bio presents a wide selection of high-quality cannabinoid elements to international pharmaceutical, nutraceutical, meals and beverage, and beauty corporations which might be able to leverage the anecdotal well being and medical advantages of CBD of their merchandise.
“Whereas we’re altering our title, our mission stays the identical: We’re a science-first firm devoted to advancing the therapeutic advantages of cannabinoids,” mentioned Mr. Wright. “Our purchasers’ successes will profit sufferers, and that is finally the place our best successes can be discovered.”
About Averix Bio
Averix Bio is in course of to be the primary botanical-based cannabinoid analysis and extraction firm within the U.S. producing 21 CFR Half 210 and Half 211-compliant merchandise. The corporate presents a full array of the highest-quality cannabinoid elements to be used within the pharmaceutical, nutraceutical, meals and beverage, and beauty sectors. Averix Bio ensures constant high quality from seed to shelf, forming the cornerstone of a company basis constructed on traceability, transparency and belief. Led by a world-class staff with cGMP/pharmaceutical expertise, Averix Bio is on a mission to deliver more healthy cannabinoid-based medical options to a worldwide client market. For extra data, go to www.averixbio.com.
SOURCE Averix Bio